Skip to main navigation
Contact Us
Join Us
LinkedIn
Our Company
About Us
Governance
Our Culture
Our Areas of Focus
Ophthalmology
Diabetic Macular Edema I OCS-01
Dry Eye Disease I Licaminlimab
Neuro-Ophthalmology
Optic Neuritis I Privosegtor
NAION I Privosegtor
Our Innovation
Pipeline
Clinical Trials
Science
Publications
Investors and Media
Column
Overview
Stock Information
News Releases
In the News
Events & Presentations
Column
Corporate Governance
SEC Filings
Public Disclosures
Investor FAQs
Investor Resources
Our Company
About Us
Governance
Our Culture
Our Areas of Focus
Ophthalmology
Diabetic Macular Edema I OCS-01
Diabetic Macular Edema I OCS-01
Dry Eye Disease I Licaminlimab
Dry Eye Disease I Licaminlimab
Neuro-Ophthalmology
Optic Neuritis I Privosegtor
Post-Ocular Surgery
NAION I Privosegtor
Dry Eye Disease
Our Innovation
Pipeline
Clinical Trials
Science
Publications
Investors and Media
Column
Overview
Stock Information
News Releases
In the News
Events & Presentations
Column
Corporate Governance
SEC Filings
Public Disclosures
Investor FAQs
Investor Resources
Event Details
Overview
Stock
Releases
In the News
Events
Governance
SEC Filings
Disclosures
FAQs
Resources
Extra menu
Extra menu
Extra menu
Overview
Stock
Releases
In the News
Events
Governance
SEC Filings
Disclosures
FAQs
Resources
Extra menu
Extra menu
Extra menu
Q4/Full Year Earnings Release
Mar 3, 2026
Visionary Innovation
Press Releases
Events
Pipeline
